NKTX Stock — Nkarta Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.73

Market cap

$123.9M

Cash

$213.3M

Enterprise value

-$89.4M

Balance sheet

Cash	$213.3M
Debt	$0.0M
Net cash	$213.3M
Enterprise value	-$89.4M
Basic shares	71.7M shares
Fully diluted shares	89.1M shares
Fully diluted market cap	$154.2M
Cash per share	$2.97
Quarterly burn	$25.8M
Cash runway	8.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

71.7M

Pre-funded warrants

3.0M

Options

10.7M

RSUs

0.9M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.8M

FDSO

89.1M

Cap table as of 2026-11-02.

Price history

Loading NKTX daily closes…

Loading price history…

Next catalyst

NKX019 · Nov 8, 2026 · guided in 1d

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDNov 8, 2026 in 1d	NKX019 Phase 1/2 Ntrust-2 initial data in idiopathic inflammatory myopathy (myositis) at ACR Convergence 2026 (oral presentation) · NCT06733935	Phase 1/2	idiopathic inflammatory myopathy (myositis) at ACR Convergence 2026 (oral presentation)	November 8, 2026
GUIDEDNov 9, 2026 in 2d	NKX019 Phase 1/2 Ntrust-2 initial data in systemic sclerosis (scleroderma) at ACR Convergence 2026 (poster presentation) · NCT06733935	Phase 1/2	systemic sclerosis (scleroderma) at ACR Convergence 2026 (poster presentation)	November 9, 2026
GUIDEDNov 11, 2026 in 4d	NKX019 Phase 1/2 Ntrust-1 and Ntrust-2 safety data in autoimmune indications at ACR Convergence 2026 (oral presentation) · NCT06557265	Phase 1/2	autoimmune indications at ACR Convergence 2026 (oral presentation)	November 11, 2026
May 13 - Jun 24 in 6 mo	NKX019	Phase 2	Lupus Nephritis; Primary Membranous Nephropathy	—
Nov 12 - Dec 24 in 25 mo	NKX019	Phase 2	Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Antineutrophil Cytoplasmic Antibody-Associated Vasculitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NKX019

Phase 2 · Active Modality: allogeneic CAR NK cell therapy

Target CD19

Partnerships University of California, Irvine (investigator-sponsored Phase 1 trial in myasthenia gravis); Columbia University Irving Medical Center (investigator-sponsored Phase 1 trial in SLE)

Indications

lupus nephritis (Ntrust-1) (Stage not disclosed)
primary membranous nephropathy (Ntrust-1) (Stage not disclosed)
systemic sclerosis / scleroderma (Ntrust-2) (Stage not disclosed)
idiopathic inflammatory myopathy (Ntrust-2) (Stage not disclosed)
ANCA-associated vasculitis (Ntrust-2) (Stage not disclosed)
rheumatoid arthritis (Ntrust-2) (Stage not disclosed)
myasthenia gravis (investigator-sponsored) (Stage not disclosed)
systemic lupus erythematosus (investigator-sponsored) (Stage not disclosed)

Status note Lead program. Ntrust-1 and Ntrust-2 are open-label dose-escalation Phase 1/2 trials; protocol amendments in April 2026 enable outpatient administration. Prior Phase 1 oncology study in B-cell malignancies closed enrollment in 2023; oncology deprioritized.

NKX101

Phase 1 · Active Modality: allogeneic CAR NK cell therapy

Target NKG2D ligands

Indications

hematologic malignancies (Stage not disclosed)

Status note Oncology Phase 1 studies for NKX019 and NKX101 closed patient enrollment in 2023 and were deprioritized to direct primary resources to NKX019 in autoimmune diseases. FDA orphan drug designation for NKX101 in acute myeloid leukemia granted December 2021.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NKX019
Lead indication	Lupus Nephritis
Lead phase	Phase 2
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06557265	Phase 2	Recruiting	Sponsor	NKTX	—	Lupus Nephritis; Primary Membranous Nephropathy	November 11, 2026
NCT06733935	Phase 2	Recruiting	Sponsor	NKTX	—	Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Antineutrophil Cytoplasmic Antibody-Associated Vasculitis	November 8, 2026 November 9, 2026
NCT04623944	Phase 1	Active, not recruiting	Sponsor	NKTX	—	Relapsed/Refractory AML; AML, Adult; MDS	—
NCT05020678	Phase 1	Active, not recruiting	Sponsor	NKTX	—	Lymphoma, Non-Hodgkin; B-cell Acute Lymphoblastic Leukemia; Large B-cell Lymphoma	—
NCT06518668	Phase 1	Enrolling by invitation	Collaborator	Hospital for Special Surgery, New York	—	Systemic Lupus Erythematosus	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Nkarta, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	10,805,129	no change	0.27%	2026-08-14
Tang Capital Partners	0	-1,480,823	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

NKTX — Nkarta Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NKTX — Nkarta Inc.